E-cigarette or vaping product use–associated lung injury without pulmonary symptoms: A case report and literature review Authors: Hanxiao Ma, Ziming Huang, Yapei Cui, Jiasheng Shen, Liang Zhang, Man Zeng, Xiaojuan Huang Published: 2026 ABSTRACT Rationale:E-cigarette or vaping product use–associated lung injury (EVALI) is a rare pulmonary condition linked to the use of e-cigarettes or vaping products. The primary symptoms of EVALI are respiratory, including shortness of breath and cough. It is rare for cases to present without pulmonary symptoms. The absence of typical symptoms often leads to clinical misdiagnosis or oversight.Patient concerns:We present a 33-year-old male with a history of e-cigarette use and allergic rhinitis. He initially sought care for recurrent nasal congestion in the absence of pulmonary symptoms; however, chest imaging unexpectedly revealed extensive lung shadows.Diagnoses:Laboratory results ruled out bacterial, fungal, and viral infections. These findings, along with his history of e-cigarette use, imaging features, and lung pathology, led to the final diagnosis of EVALI.Interventions:The patient then received glucocorticoid therapy: oral prednisone acetate tablets 20 mg once daily for 14 days followed by a standardized tapering regimen.Outcomes:His condition showed clinical improvement with glucocorticoid therapy, and lung shadows were reduced on imaging. A 2-year follow-up revealed no signs of recurrence.Lessons:We emphasize that although EVALI without pulmonary symptoms is rare, it should be included in the differential diagnosis for individuals with a history of e-cigarette use who present with atypical or extrapulmonary manifestations. 1. Introduction First designated in 2019, e-cigarette or vaping product use–associated lung injury (EVALI) represents a distinct clinical entity of acute or subacute respiratory illness attributable to the use of e-cigarettes or vaping products.[1] Epidemiologically, the majority of EVALI cases have been reported in the United States, predominantly affecting adolescents and young adults, with a consistent male predominance across cohorts.[2] The clinical burden of EVALI is substantial: pooled estimates indicate that 94.4% of patients require hospitalization, 35.7% require intensive care unit admission, and the overall mortality rate is 0.9%, underscoring the critical acuity of this condition.[3] The clinical spectrum of EVALI encompasses manifestations ranging from asymptomatic presentations to respiratory compromise and, in severe cases, respiratory failure.[4] In addition to pulmonary involvement, a subset of patients may present with concurrent gastrointestinal, cardiac, and systemic symptoms, including nausea, vomiting, chest pain, fever, and weight loss. In current literature, among reported cases of patients, there have only been 3 patients who lacked pulmonary symptoms.[5,6] Herein, we report on a patient with EVALI who lacked typical pulmonary symptoms throughout the clinical course. We review the pertinent literature to enhance clinical recognition, facilitate accurate diagnosis, and guide appropriate management of this respiratory illness. 2. Case presentation A 33-year-old male presented to the Otolaryngology Department of Guangdong Clifford Hospital on August 17, 2023, for recurrent nasal congestion lasting over a year. After admission, chest noncontrast computed tomography (CT) revealed scattered opacities in both lungs (Fig. 1A and B), prompting his transfer to the Respiratory Department for further management. His symptoms included nasal congestion, intermittent minor epistaxis, occasional nasal itching, sneezing, clear rhinorrhea, and snoring during sleep. Treatment with budesonide nasal spray for 2 weeks showed no improvement. The patient had no pulmonary complaints such as cough, shortness of breath, or chest pain upon admission. He had used e-cigarettes with mung bean flavoring for 3 years, with a daily consumption of 7 to 13 puffs, and had a previous 10-year history of tobacco smoking at 15 cigarettes per day. The patient had no history of dust or other allergies and no other medical history. Comparison of baseline and follow-up chest CT scans. (A/a, B/b) Baseline imaging shows multiple scattered opacities in both lungs. A large, patchy consolidation with an air bronchogram is present in the anterior medial basal segment of the left lower lobe. On contrast‑enhanced series, the lesion demonstrates moderate progressive enhancement. (C/c) After ineffective anti‑infective therapy, the pulmonary lesions increased in both number and size(arrows). (D/d) Following glucocorticoid treatment, the areas of pulmonary infiltration decreased compared with previous scans(arrows). (E/e) At the 2‑year follow-up, the lung lesions had resolved substantially, with only minor organized foci remaining in the left lower lobe(arrows). Physical examination revealed a peripheral oxygen saturation of 98% on room air, and auscultation of both lungs revealed clear breath sounds without crackles or wheezes. Laboratory tests showed the following: white blood cell count 13.62 × 109/L (reference range: 3.5–9.5 × 109/L), absolute neutrophil count 8.99 × 109/L (reference range: 1.8–6.3 × 109/L), a C-reactive protein level of 14.4 mg/L (reference range: <10.0 mg/L), and an erythrocyte sedimentation rate of 17 mm/h (reference range: 0–15 mm/h). The patient underwent a thorough microbiological examination, including bronchoalveolar lavage fluid (BALF) pathogen analysis (including bacterial/fungal culture, smear, and tests for Mycobacterium tuberculosis), serum galactomannan antigen test, serum (1,3)-β-d-glucan test, Mycoplasma antibody test, and cryptococcal antigen test, all of which were negative. Testing for influenza A virus, influenza B virus, and SARS-CoV-2 antigens was also negative. Human immunodeficiency virus test and hepatitis B virus test were negative. Allergy testing, including both skin prick testing and immunoglobulin E detection, was negative. Carcinoembryonic antigen, autoimmune antibodies, and electrocardiogram results were all within normal limits. The 5-item vasculitis panel, including anti-neutrophil cytoplasmic antibodies (pANCA and cANCA), anti-myeloperoxidase antibody, anti-proteinase 3 antibody, and anti-cardiolipin antibody, was negative. Chest CT showed multiple scattered patchy, nodular, and mass-like areas of increased density in both lungs, primarily distributed subpleurally, with ill-defined margins. A larger lesion was located in the anterior medial basal segment of the left lower lobe, containing an air bronchogram (Fig. 1A/a and B/b). Sinus CT indicated bilateral maxillary sinus submucosal cysts and right concha bullosa. Nasal endoscopy revealed a “deviated nasal septum, chronic rhinitis.” Pulmonary function tests were not performed, as the patient was clinically stable with no respiratory distress and normal resting oxygen saturation. 2.1. Subsequent procedures and pathology The patient subsequently underwent bronchoscopy. The bronchoscopic view of the anterior basal segment of the left lower lobe showed a patent bronchus with congested mucosa and no neoplasm. A radial endobronchial ultrasound-guided transbronchial lung biopsy was performed in the anterior basal segment of the left lower lobe (Fig. 2A and B). The pathological examination of the lung biopsy revealed moderate aggregates of lymphocytes and plasma cells with a few eosinophils; neutrophils were rare. Some alveolar septa were widened, with type II pneumocyte hyperplasia. The alveolar spaces contained a moderate number of macrophages phagocytosing neutral fat (Fig.3A and B). BALF cytological differential was as follows: macrophages 53%, neutrophils 26%, lymphocytes 15%, ciliated columnar epithelial cells 4%, squamous epithelial cells 2%, eosinophils 0%. Based on the history of e-cigarette use, laboratory tests, imaging, and pathological findings, he was diagnosed with EVALI combined with allergic rhinitis (AR). (A) Bronchoscopic view. (B) Radial ultrasound exploration detecting abnormal echogenicity in the anterior basal segment of the left lower lobe. (A) Histopathological examination of lung tissue revealed a moderate number of macrophages phagocytosing neutral fat within the alveolar spaces (arrow). (B) Cytological examination of bronchoalveolar lavage fluid showed foamy macrophages (arrow). On admission, the patient had no pulmonary symptoms, but elevated white blood cell and neutrophil counts were noted. Therefore, only empirical antibiotic therapy was initiated during hospitalization: intravenous ceftriaxone 2 g once daily for 7 days, followed by oral sequential moxifloxacin 400 mg once daily for 7 days. However, the reexamination of the contrast chest CT 1 month after completing anti-infective therapy indicated progression of the lesions with an increased number and size, suggesting treatment failure (Fig. 1C/c). Given the lung biopsy pathology, EVALI was considered, and the patient was instructed to discontinue e-cigarette use, which he complied with. The patient then received glucocorticoid therapy: oral prednisone acetate tablets 20 mg once daily for 14 days, followed by a standardized tapering regimen. A chest CT reexamination half a month after steroid initiation showed a significant reduction in lung lesions, indicating a good therapeutic response (Fig. 1D/d). A 2-year follow-up chest CT revealed only minimal residual organizing foci in the left lower lobe, with no signs of recurrence. For AR, nasal corticosteroid treatment did not resolve the epistaxis, and the patient had severe nasal septal deviation. After the improvement of EVALI symptoms, he underwent endoscopic septoplasty under general anesthesia. Postoperatively, his symptoms of nasal congestion and epistaxis resolved. No recurrence was reported at the 2-year follow-up (Fig. 1E/e). 3. Discussion In recent years, the use of e-cigarettes has surged, with over 68 million users in more than 60 countries globally.[7] In the United States, e-cigarette use is most common among adolescents, while in China, it is most prevalent among young and middle-aged males.[8] EVALI was first reported in July 2019. As of February 2020, when the US Centers for Disease Control and Prevention stopped updating case counts, over 2807 hospitalizations and 68 deaths had been attributed to EVALI.[9,10] This case represents a less typical presentation of EVALI due to the absence of pulmonary complaints. To date, only 3 cases of EVALI without respiratory symptoms have been reported in the literature.[10] However, all presented with other systemic symptoms such as nausea, vomiting, and weight loss. In contrast, the patient in this report exhibited nasal congestion and sneezing, which are likely attributable to his preexisting AR rather than EVALI. It is plausible that he presented early in the course of his illness, before pulmonary symptoms could manifest.[5] Furthermore, this low reported proportion may stem from the fact that asymptomatic or mildly symptomatic individuals often do not seek medical attention and therefore do not undergo relevant diagnostic investigations, leading to their underrepresentation in clinical series and epidemiological data. The exact pathological mechanism of EVALI remains unclear. Current understanding suggests it is primarily associated with vitamin E acetate and tetrahydrocannabinol added to e-liquids.[11,12] Aerosols from e-cigarettes cause cellular oxidative damage, alter cell phenotypes, and impair host immunity, collectively leading to acute or subacute lung injury.[13] The clinical presentation and severity of EVALI are contingent upon several factors, including e-cigarette device parameters, the chemical composition of the e-liquid, duration of exposure, and the individual’s preexisting health status. Furthermore, evidence suggests that fruit-flavored e-cigarettes possess a higher oxidative potential than tobacco-flavored variants and may therefore pose a greater risk.[14] The radiological and histopathological findings in EVALI are relatively nonspecific in many cases. Organizing pneumonia is the pattern of lung injury observed in 70% of EVALI cases. In acute or more severe cases, patterns of acute fibrinous pneumonia or diffuse alveolar damage may be seen.[15] Chest imaging findings include pulmonary infiltrates, such as opacities on chest X-ray or ground-glass opacities on CT. Lung biopsy in EVALI shows histological evidence of subacute to acute lung injury, often featuring fibroblastic plugs, hyaline membranes, fibrin exudates, type II pneumocyte hyperplasia, and interstitial chronic inflammatory infiltration.[16] BALF analysis reveals increased numbers of macrophages or neutrophils and foamy macrophages.[17] On imaging, subpleural opacities were observed on contrast-enhanced CT. Histopathology further indicated alveolar damage with type II pneumocyte hyperplasia and lipid-laden macrophages. In addition, bronchoalveolar lavage cytology demonstrated macrophage predominance and an increased neutrophil proportion. Collectively, these features align with the diagnostic profile of EVALI. EVALI remains a diagnosis of exclusion.[1] The case definition established by the US Centers for Disease Control and Prevention is widely accepted. Diagnosis primarily relies on a history of e-cigarette use, characteristic imaging findings, and the exclusion of other respiratory pathogens or alternative plausible diagnoses. This patient was an immunocompetent young male with no other significant medical history. He had used e-cigarettes for 3 years, presented without obvious pulmonary symptoms like cough or sputum, and a contrast-enhanced chest CT showed large areas of increased density. Serum and BALF tests ruled out bacterial, fungal, viral, and tuberculous infections, as well as malignancy. No evidence of rheumatic or cardiac disease was identified based on the patient’s history, blood tests, or relevant investigations. Therefore, despite the absence of pulmonary symptoms, this patient met the accepted case definition for EVALI based on a clear history of e-cigarette use, characteristic radiographic findings, and the comprehensive exclusion of alternative infectious and other causes. To date, no specific guidelines for the treatment of EVALI have been published. Clinical management of EVALI centers on the discontinuation of e-cigarette use, and hospitalization is recommended for patients with respiratory distress.[6,18] The treatment regimen includes early administration of glucocorticoids, with dose and duration requiring individualized assessment.[19] Empirical antibiotics or antivirals may be used based on the clinical scenario. Respiratory support such as supplemental oxygen, noninvasive ventilation, or mechanical ventilation is provided for breathing difficulties. The vast majority of patients improve and eventually recover after stopping e-cigarette use and receiving systemic steroid therapy. In this case, the patient commenced on prednisone tablets at 20 mg daily. Follow-up imaging after 2 weeks of treatment showed resolution of the lesions compared to previous studies. The dose was subsequently tapered off over an additional week. To date, the patient has been followed up for 2 years, with no signs of recurrence observed. This condition should be differentiated from cryptogenic organizing pneumonia (COP). Both share features like lack of response to antibiotics, efficacy of glucocorticoids, and elevated inflammatory markers. However, COP typically presents with characteristic imaging findings of bilateral patchy or diffuse consolidation or ground-glass opacities, positive related autoimmune antibodies, and a lung biopsy showing granulation tissue. Intra-alveolar granulation tissue plugs (Masson bodies) were absent in this patient, and none of the typical imaging and serological manifestations of COP were observed in the case.[20] This case illustrates an atypical presentation of EVALI characterized by the absence of respiratory symptoms and complicated by AR, suggesting that EVALI exacerbates the clinical symptoms of AR. Evidence supports this association, indicating a significantly higher prevalence of AR among e-cigarette users, particularly former traditional smokers who have switched to vaping.[21,22] E-cigarette aerosols contain irritants such as aldehydes and reactive oxygen species, which can activate nasal epithelial cells and trigger a local inflammatory response, marked by the release of pro-inflammatory cytokines.[23] This process may induce or exacerbate AR-related mucosal inflammation, edema, and hypersecretion.[24] This underscores the importance of considering EVALI in the differential diagnosis of patients with a history of e-cigarette use, even in the absence of typical pulmonary complaints, especially when concomitant upper airway conditions such as AR are present. This case has the following limitations: first, due to cost concerns, the patient declined metagenomic next-generation sequencing of BALF. Second, due to testing constraints, analysis of vitamin E acetate and tetrahydrocannabinol components related to EVALI in the BALF was not performed. 4. Conclusions We report a case of EVALI combined with AR in a patient without pulmonary symptoms. For patients presenting with CT findings suggestive of acute lung injury but no other clear etiology, especially in this population, clinical history-taking should include investigation of e-cigarette exposure history, and the possibility of concurrent EVALI should be considered. In this clinical scenario, strict cessation of e-cigarette use combined with glucocorticoid therapy appears safe and effective.